eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2024
vol. 20
 
Share:
Share:
Image in intervention

Transient ST-elevation myocardial infarction and conservative, optical coherence tomography-guided, deferred treatment for late stent thrombosis: what is the ideal antithrombotic regimen and deferral period?

George Kassimis
1
,
Sotirios Mitsiadis
2
,
Konstantinos C. Theodoropoulos
3
,
Antonios Ziakas
3
,
Nikolaos Fragakis
1

  1. 2nd Cardiology Department, Hippokration Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
  2. 3rd Cardiology Department, Hippokration Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
  3. 1st Cardiology Department, AHEPA General Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
Adv Interv Cardiol 2024; 20, 3 (77): 362–364
Online publish date: 2024/08/13
Article file
- transient ST.pdf  [0.26 MB]
Get citation
 
 

A 65-year-old man presented to the emergency department with a transient anterior-wall ST-elevation myocardial infarction (STEMI) (Figures 1 A, B). The patient had a history of percutaneous coronary intervention (PCI) to proximal left anterior descending artery (LAD) 3 months prior this acute admission. Dual antiplatelet therapy was erroneously interrupted for 7 days in the context of an elective dental procedure.

Figure 1

A – Electrocardiogram (ECG) taken in the Emergency Department at the onset of chest pain with anterior STEMI. B – ECG repeated 30 min after the first ECG, when chest pain had completely resolved, showing complete ST-segment resolution before cardiac catheterization. C – Index coronary angiogram with appearance of proximal left anterior descending (LAD) stent thrombosis (white arrow). D – Repeat angiogram after 5 days of intensive antithrombotic therapy, showing patent LAD stent with complete resolution of thrombus. D 1, 2 – Optical coherence tomography confirmed adequate expansion of the stent throughout its full length, complete apposition of the struts to the vessel wall and lack of edge dissection

/f/fulltexts/PWKI/54613/PWKI-20-54613-g001_min.jpg

The patient was loaded with aspirin and ticagrelor and even though emergency coronary angiogram showed stent thrombosis in the proximal LAD, there was thrombolysis in myocardial infarction (TIMI) 3 flow (Figure 1 C). Due to the high thrombus burden and relief of symptoms, procedure was deferred, and the patient was put on intravenous (IV) tirofiban infusion for 18 h along with subcutaneous low molecular weight heparin (LMWH) therapeutic dose and dual antiplatelet therapy (DAPT) with aspirin and ticagrelor. The repeat angiogram after 5 days showed a patent LAD stent with complete resolution of the thrombus (Figure 1 D). Optical coherence tomography (OCT) using the Gentuity HF-OCT Imaging System with the Vis-Rx Micro-Imaging Catheter (Nipro Medical Europe, Nipro European HQ, Blokhuisstraat 42, 2800, Mechelen, Belgium) confirmed the adequate expansion of the previously implanted stent in its full length, complete apposition of the stent struts to the vessel wall and lack of edge dissection (Figure 1 D 1, 2). It was therefore decided to administer conservative treatment. Peak hs-cTn was 70 ng/l and BNP level 310 pg/ml. The patient was symptom-free at 3 months follow-up.

Up to 1 out of 4 patients who initially present with a STEMI may subsequently show complete resolution of symptoms and ST elevation before revascularization therapy is initiated [1]. This condition is called ‘transient STEMI’. Augmented endogenous fibrinolysis has been found in such patients, who appear to have a more favorable prognosis with smaller infarct size compared to patients with persistent STEMI [1]. According to the PLATO trial, rapid clot lysis is a strong independent predictor of favorable outcome in STEMI patients, independent of their antiplatelet therapy [2]. Fibrinolysis is not mediated by oral antiplatelet medication. Therefore, an intense parenteral antithrombotic therapy is warranted, as in our patient.

In our institution, in cases of high thrombus burden and a deferred procedure, we administer an IV GP IIb/IIIa inhibitor for 18 h after the diagnostic procedure on top of DAPT and a therapeutic dose of LMWH and then, following interruption of the GP IIb/IIIa inhibitor, triple antithrombotic therapy for 5–7 days. The usual time elapsed is 24–72 h in the randomized controlled trials (RCT) except INNOVATION, which used a time lag of 3–7 days. Similarly, the majority of the 10 non-RCT studies also used a time delay between 24 and 72 h [3]. Only four studies have used a longer, 6–7-day window period for deferral [3]. Many researchers, including our group, consider the 24–48-hour window period too short for thrombus resorption and effective action of antithrombotic agents.

Ethical approval

Not applicable.

Conflict of interest

The authors declare no conflict of interest.

References

1 

Janssens GN, Lemkes JS, van der Hoeven NW, et al. Transient ST-elevation myocardial infarction versus persistent ST-elevation myocardial infarction. An appraisal of patient characteristics and functional outcome. Int J Cardiol 2021; 336: 22-8.

2 

Sumaya W, Wallentin L, James SK, et al. Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Heart J 2018; 39: 1078-85.

3 

Pradhan A, Bhandari M, Vishwakarma P, Sethi R. Deferred stenting for heavy thrombus burden during percutaneous coronary intervention for ST-elevation MI. Eur Cardiol 2021; 16: e08.

Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.